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In this issue of Blood, Shide et al. separate the roles of loss of a normal CALR allele and gain of a 
mutant CALR allele in CALR-driven essential thrombocythaemia (ET)1. 
Approximately one in four patients with ET, a blood cancer characterized by over-production of 
platelets, has a frameshift mutation in the gene encoding calreticulin (CALR)2,3. Research to date has 
demonstrated a gain-of-function role for the frameshifted CALR protein in binding to the 
thrombopoietin receptor (TpoR), thus acting as a rogue ligand and triggering proliferation and 
megakaryopoiesis. However, there has been less investigation of the effects of the loss of a normal 
CALR allele: CALR-/- mice are embryonic lethal due to malformation of the heart, preventing study of 
haematopoiesis in these mice4.  
Shide et al. generated a mouse with haematopoietic-specific deletion of the CALR allele to allow 
separation of gain- and loss-of-function effects of the CALR mutation. Loss of one or both CALR 
alleles in haematopoietic cells had little effect on bone marrow haematopoiesis and did not cause 
ET, though loss of both alleles increased extramedullary haematopoiesis. In transplantation 
experiments, loss of one or both alleles increased bone marrow repopulation in primary recipients, 
but only loss of a single allele maintained this advantage in secondary transplants, indicating that 
CALR haploinsufficiency yields a competitive advantage. The authors further demonstrate that a 
CALRdel52 transgene can only drive a MPN phenotype (thrombocytosis) in transplants when WT 
CALR is haploinsufficient. Finally, they use transcriptomic data to investigate potential mechanisms 
underlying the advantage of CALR+/- cells. Compared to WT stem/progenitor cells, they find that 
CALR+/- cells have increased expression of E2F targets, suggestive of higher cell cycling. When 
comparing WT and CALR+/- cells also expressing transgenic CALRdel52, the authors again show 
upregulation of E2F target genes, in addition to an increase in stem cell self-renewal pathways and 
decreases in pathways responsive to the pro-inflammatory cytokines TNF-α and IFN-γ.  
These results advance the field in several ways, not least by demonstrating a previously unknown 
role for normal CALR in haematopoiesis. Additionally, they shed light on important questions about 
differences between mouse models and human patients: while human patients typically show clonal 
disease, mouse models to date have shown either no5,6 or a slow-rising7 competitive advantage. The 
results of Shide et al. suggest that an approach wherein two WT CALR alleles are maintained6 may 
show no competitive advantage, as this requires loss of a normal CALR allele. Therefore, knock-in 
approaches may be more informative, as they more closely resemble patients. One mouse model 
with knock-in of a humanized CALRdel52 allele gave rise to a strong ET phenotype but no advantage 
within transplants5. A separate CRISPR-Cas9-based mouse model of the CALRdel52 mutation within 
the mouse CALR gene exhibited a lower platelet phenotype and a slow-rising competitive advantage 
in primary transplants, consistent with the requirement for CALR haploinsufficiency to yield a stem 
cell advantage7. The differences between the models remain unresolved, but may reflect differences 
in how murine and human frameshifted CALR protein bind to TpoR7 or other differences in the 
generation of the models. Furthermore, the results of Shide et al. emphasize that the level of 
CALRdel52 expression is crucial: progression to myelofibrosis in mouse models is only seen when 
CALRdel52 is highly expressed, as via retroviral expression6 or homozygosity of the knocked-in 
CALRdel52 allele5. Together, these results underscore the importance of ensuring that model 
systems resemble the situation in human patients, who have one mutant and one wild-type allele. 
Similarly, while results from transplant experiments can give insight into stem cell function, it is 
important to remember that these are artificial settings that do not resemble steady state 
haematopoiesis in patients. 
Going forward, more research will be necessary to understand why CALR haploinsufficiency is so 
critical to bestow a competitive advantage on stem cells: while there are indications of increased cell 
cycling and self-renewal, no direct mechanism has been proposed. It remains to be seen if this 
mechanism will rely on one of the canonical functions of CALR, such as protein chaperoning or 
calcium signalling8, or if the mechanism will be as surprising as the discovery of TpoR activation by 
frameshifted CALR protein. As the transcriptomic data were obtained from stem/progenitor cells 
from transplant recipients, they may be confounded by the stresses of the transplantation protocol 
on both donor cells and the recipient bone marrow niche. Overall, this study is an important advance 
in our understanding mutant CALR-driven ET: in addition to the well-studied role of mutant CALR as 
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